Linezolid Use in Multidrug‑Resistant Tuberculous Meningitis

Dosing Recommendations

Initial dose of 600 mg oral linezolid once daily is recommended for adults with MDR‑TB meningitis; this dose provides adequate efficacy while limiting toxicity. (American Thoracic Society/CDC/ERS/IDSA) 1
A 600 mg daily regimen results in significantly fewer adverse events than 1,200 mg daily (46.7 % vs 74.5 % of patients) without loss of effectiveness. (American Thoracic Society/CDC/ERS/IDSA) 2
Starting doses lower than 600 mg daily are not supported by current evidence for MDR‑TB meningitis. (American Thoracic Society/CDC/ERS/IDSA) 2

Children should receive linezolid 10 mg/kg every 8 hours (three times daily), not every 12 hours as in adults. (American Thoracic Society) 5
Myelosuppression is especially common in children younger than 10 years receiving the 10 mg/kg twice‑daily regimen. (American Thoracic Society) 1

Linezolid should be continued throughout the intensive phase and for the remainder of an approximately 18‑month MDR‑TB meningitis regimen. (American Thoracic Society) 1
The total duration should be individualized according to disease extent, drug‑resistance pattern, and clinical response. (American Thoracic Society) 5

The 6‑month BPaLM regimen (bedaquiline + pretomanid + linezolid 600 mg + moxifloxacin) is not recommended for CNS‑involved TB meningitis because efficacy data are lacking. (International Society of Infectious Diseases) 7
No evidence supports short‑course (≤6 months) regimens for meningeal tuberculosis. (International Society of Infectious Diseases) 7

Hematologic monitoring for myelosuppression (anemia, leukopenia, pancytopenia, thrombocytopenia) is essential; adverse events are frequent. (American Thoracic Society) 1
Neurologic monitoring for peripheral neuropathy and optic neuritis should be performed monthly, as toxicity typically emerges after 12–20 weeks of therapy. (American Thoracic Society) 4
Neurotoxicity correlates with linezolid trough concentrations > 2.0 mg/L; therefore therapeutic drug monitoring is advised, targeting trough < 2.0 mg/L. (American Thoracic Society) 1
Therapeutic drug monitoring is recommended to reduce adverse events by keeping trough levels below 2.0 mg/L. (American Thoracic Society) 2

Hematologic toxicity occurs in approximately 71 % of patients (anemia, leukopenia, thrombocytopenia). (American Thoracic Society) 3
Neurologic toxicity occurs in about 65 % of patients (peripheral neuropathy, optic neuritis). (American Thoracic Society) 3
Gastro‑intestinal disturbances, hyperlactatemia, and diarrhea are less common. (American Thoracic Society) 3

Concurrent use of serotonergic agents (e.g., MAO inhibitors, SSRIs) is contraindicated because of the risk of serotonin syndrome or neuroleptic malignant syndrome. (American Thoracic Society) 8
Clarithromycin markedly increases linezolid serum exposure and should be avoided or dose‑adjusted. (American Thoracic Society) 8

Patients with baseline hemoglobin < 7 g/dL or platelet count < 75 000 mm³ should preferentially receive linezolid‑sparing regimens when feasible. (International Society of Infectious Diseases) 7

Regimens that include linezolid reduce mortality (adjusted OR 0.30, 95 % CI 0.20–0.30) and increase treatment success (adjusted OR 3.40, 95 % CI 2.60–4.50) compared with regimens without linezolid. (American Thoracic Society) 2
In extensively drug‑resistant TB, the mortality benefit is even greater (adjusted OR for death 0.10, 95 % CI 0.10–0.20). (American Thoracic Society) 2
Combining bedaquiline with linezolid yields synergistic effects, further lowering mortality (adjusted OR 0.30, 95 % CI 0.20–0.40). (American Thoracic Society) 2

The ATS/CDC/ERS/IDSA guideline issues a conditional recommendation for including linezolid in MDR‑TB meningitis regimens, citing higher adverse‑event rates relative to bedaquiline and fluoroquinolones. (American Thoracic Society) 9
The WHO guideline provides a strong recommendation for longer MDR/RR‑TB regimens that incorporate linezolid. (World Health Organization) 10

Confirm MDR‑TB meningitis diagnosis with drug‑susceptibility testing. (International Society of Infectious Diseases) 7
Start linezolid 600 mg daily as part of a multidrug regimen that includes bedaquiline and a fluoroquinolone. (American Thoracic Society; WHO) [1][10]
Obtain baseline complete blood count, visual‑acuity testing, and peripheral‑nerve examination before initiating therapy. (American Thoracic Society) 1
Monitor complete blood count weekly and neurologic function monthly throughout treatment. (American Thoracic Society) 1
If optic neuritis develops, discontinue linezolid and consider rechallenge at 300 mg daily after visual recovery. (American Thoracic Society) 4
Continue linezolid for a total of ≥18 months as part of an individualized MDR‑TB meningitis regimen. (American Thoracic Society) 5